ANDRA COCOLOS, ADINA GHEMIGIAN, NICOLETA DUMITRU, EUGENIYA NEDELTCHEVA PETROVA, MIRCEA GHEMIGIAN, ANDRA CARAGHEORGHEOPOL, DUMITRU IOACHIM, CATALINA POIANA LOWER VITAMIN D STATUS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA Thyroid cancer (TC) has become the most rapidly increasing type of cancer representing 1-1.5% of all cancers diagnosed annually probably due to intensive screening. It is estimated that the death rate of TC has slowly increased from 0.49 to 0.51/100.000 in the last 10 years and 53.990 new cases will be diagnosed in 2018 in the United States. Therefore, efforts are being made in order to stop the increasing incidence and genetic alterations are thoroughly studied. One of the most recent incriminated factors in TC etiology and physiopathology is vitamin D deficiency. Besides the well-known role in bone metabolism, vitamin D has extra-skeletal effects exerted through the vitamin D receptor (VDR) and has been shown to interfere with many cellular functions such as inhibiting cell proliferation, stimulating differentiation and malignant cell apoptosis in different types of cancer. Cross-sectional, retrospective study which included 114 patients (71 with confirmed thyroid cancer and 43 patients in the control group with benign pathology). Preoperative levels of 25(OH)vitamin D, PTH, biochemical and thyroid panel were measured. The histopathologic features were analyzed. Mean values of vitamin D was 16.31 ± 7.14 ng/mL with lower levels in patients with thyroid cancer (14.95 ± 5.91 ng/mL) in comparison to patients with benign thyroid pathology (18.55 ± 8.41 ng/mL), with a p value of 0.008. Majority of the cases were papillary thyroid cancer (97.18%) in stage 3 (45.07%). Vitamin D levels also correlated negatively with TNM staging. The necessity of further studies is a reality in order to establish if vitamin D deficiency is a possible risk factor for thyroid cancer and its correction can be considered an additional therapy.
Keywords: thyroid cancer, vitamin D, 25-hydroxyvitamin D